Ian Roullier

Ian is the co-founder of the Psychedelic Participant Advocacy Network (PsyPAN) and an expert by experience, having taken part in two clinical trials examining the effect of psilocybin on treatment-resistant depression at Imperial College (2015) and King’s College (2019). He has spoken at the European Parliament, European Medicines Agency and at various events and conferences. Ian is also an ACER Integration sharing circle facilitator and a participant representative for the King’s College PsiDeR trial steering group. He co-founded PsyPAN with Leonie Schneider in 2021 to help amplify and represent participant voices, help safeguard future participants receiving psychedelic-assisted therapy and establish peer support spaces post-treatment.

Leonie Schneider

Leonie is a passionate mental health advocate, committed to expanding access to psychedelic assisted therapies by advocating for the safe and integrated use of psychedelics. After participating in a Psilocybin for Depression trial at Imperial College (2019) and Small Pharma’s DMT for Depression trial (2022), she co-founded the Psychedelic Participant Advocacy Network (PsyPAN) with Ian Roullier to help inform the delivery of trial and treatment design from a participant perspective.

Leonie has spoken extensively on national and international platforms including the BBC, ICPR and the upcoming Psychedelic Chronicles documentary. She is also a circle facilitator for the ACER Integration Community and is training in transpersonal psychotherapy.

Leonie’s recognition as one of the top 20 influential, innovative, and disruptive Women in Psychedelics speaks to her commitment to enhancing participant well-being and improved outcomes for all who access these treatments.

Michael Bourne

Michael’s journey into psychedelics began with participation in the ground-breaking 2015 Imperial College clinical trial exploring psychedelics for depression. Since then, Michael has become a vocal advocate for the therapeutic potential of psychedelics, sharing experiences and insights at various conferences and in clinical research scenarios. Michael is a member of the steering committee for the Psychedelics for Depression (PsiDeR) trial, based at King’s College London and works with PsyPAN, the Psychedelic Participant Advocacy Network. Michael is deeply intrigued by the intersection of music and psychedelics, experimenting with musical tracks that explore the profound ways in which music and sound design can shape the psychedelic experience.

Katharine Lazenby

Katharine is an expert by experience, drawing on her lived experience of mental illness, psychiatric care and inpatient hospitalisation in a variety of roles. Based in London, she has worked for an NHS mental health trust for the last six years and is also a trustee for two mental health charities. Katharine also delivers mental health training to health and social care staff across North East London, is a visiting scholar at London Southbank University and has spoken at a number of conferences. She is particularly passionate about the impact treatment settings, especially ward environments, can have on patient wellbeing and the power of art and creativity in nurturing recovery. Katharine took part in a psychedelic clinical trial in 2022, and has become a committed advocate for research into the potential of psychedelics in the treatment of mental illnesses and recovery support.